


N6-(4-Hydroxybenzyl)adenosine

Cat. No.:	HY-18775		
CAS No.:	110505-75-4		
Molecular Formula:	C ₁₇ H ₁₉ N ₅ O ₅		
Molecular Weight:	373.36		
Target:	P2Y Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (267.84 mM)
 H₂O : 1 mg/mL (2.68 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		2.6784 mL	13.3919 mL	26.7838 mL
	5 mM		0.5357 mL	2.6784 mL	5.3568 mL
	10 mM		0.2678 mL	1.3392 mL	2.6784 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

N6-(4-Hydroxybenzyl)adenosine is an inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC₅₀: 6.77-141 μM). IC₅₀ value: 6.77-141 μM Target: P2Y₁₂receptor Anti-aggregation activity of N6-(4-Hydroxybenzyl)adenosine could involve an interaction with the P2Y₁₂receptor binding site.

REFERENCES

[1]. Vistoli G, et al. Naturally occurring N(6)-substituted adenosines (cytokinin ribosides) are in vitro inhibitors of platelet aggregation: an in silico evaluation of their interaction with the P2Y(12) receptor. Bioorg Med Chem Lett. 2014 Dec 15;24(24):5652-5655.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA